All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2019-09-24T13:20:22.000Z

1st NCRI AML academy meeting | The David Grimwade Memorial Lecture

Bookmark this article

In this video from the 1st NCRI AML academy meeting, Professor Charles Craddock, Queen Elizabeth Hospital, Birmingham, UK, introduces the David Grimwade Memorial Lecture, given by Professor Gert Ossenkoppele.

Professor Craddock pays homage to his colleague and friend, David Grimwade, who passed away in October 2016, by detailing his commitment to the field of hematology, his passion for patient care and his fun nature. David Grimwade was at the forefront of research into the pathogenesis of acute promyelocytic leukemia (APL) and pioneered the application of measurable residual disease (MRD) management into clinical practice. He was also one of the first to extend this to acute myeloid leukemia (AML) and stem cell transplantation. His belief of tailoring therapy in AML had a global impact and provided a prime example that advances in basic science could rapidly be applied to clinical practice.

Professor Craddock pays tribute to David's fun nature with anecdotal stories of their congress travel together and highlights how David's interactions between the laboratory and the clinic, attention to detail, infectious spirit of enquiry and academic collaboration should inspire us to work together to transform patient care.

The David Grimwade Memorial Lecture

Your opinion matters

Do you intend to implement next-generation sequencing for measurable residual disease monitoring in MDS patients?
1 vote - 3 days left ...

Newsletter

Subscribe to get the best content related to AML delivered to your inbox